Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Study sponsor: ImmunityBio, Inc. · IBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2017-05-15Actual
Enrollment · participants135Actual
Source updated2024-06-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.